879551-04-9 Usage
Description
(3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxyMethyl)-3-Methyl-dihydrofuran-2(3H)-one is a complex organic compound with a unique molecular structure, featuring a fluorinated dihydrofuran ring and multiple chiral centers. Its stereochemistry is defined by the (3R,4R,5R) configuration, which is crucial for its potential applications in asymmetric synthesis.
Uses
Used in Pharmaceutical Industry:
(3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxyMethyl)-3-Methyl-dihydrofuran-2(3H)-one is used as a key intermediate in the asymmetric synthesis of complex organic molecules, particularly for the preparation of dibenzoyl fluoro methyl-D-ribono-γ-lactone. (3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxyMethyl)-3-Methyl-dihydrofuran-2(3H)-one is synthesized via asymmetric aldol condensation and enzymic hydrolysis from isopropylidene-D-glyceraldehyde and Et fluoropropionate, showcasing its importance in the development of novel pharmaceutical agents and advanced drug delivery systems.
Check Digit Verification of cas no
The CAS Registry Mumber 879551-04-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,9,5,5 and 1 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 879551-04:
(8*8)+(7*7)+(6*9)+(5*5)+(4*5)+(3*1)+(2*0)+(1*4)=219
219 % 10 = 9
So 879551-04-9 is a valid CAS Registry Number.
879551-04-9Relevant articles and documents
BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E
-
, (2021/10/22)
The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.
PROCESS FOR PREPARATION OF LACTONE DERIVATIVES AND INTERMEDIATES THEREOF
-
Page/Page column 36; 37, (2018/03/09)
A novel process for the preparation of lactone derivatives, and intermediates thereof is described. The lactone derivatives are important precursors for the synthesis of anti-hepatitis C virus agents, including sofosbuvir.
Synthesizing method for drug intermediate
-
Paragraph 0103-0106; 0111-0113; 0117-0119, (2017/06/02)
The invention discloses a synthesizing method for a drug intermediate, and relates to the field of drug synthesis, in particular to the field of organic synthesis. In the synthesizing method, compound V(4S,5R)-ethyl-5-((R)-2,2-dimethyl-1,3-dioxolame-4-base)-4-methyl-1,3,2-dioxathiolane-4- carboxylic acid-2,2'dioxide serves as a raw material, a compound II is prepared through three synthesizing methods, and an intermediate compound I is prepared through the compound II. The provided synthesizing technology has the beneficial effects that cost is low, few byproducts are generated, the yield is high, and pollution to the environment is weak.